'TWIST' AND DOUBT
Valeant $45B Allergan bid clever, but will board go along?
By Randy Osborne
Tuesday, April 22, 2014
As Tuesday wore on, skepticism gave way regarding success for the hostile try by Valeant Pharmaceuticals International Inc., with help from the hedge fund Pershing Square Capital Management L.P., to take over Allergan Inc. in a deal valued at about $45 billion. But the merger is by no means a deal.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.